ArticleERJ open research2026
Hippo pathway activation drives fibrogenic remodelling in influenza A virus-infected lung fibroblasts.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis is a progressive and often fatal interstitial lung disease with largely undefined aetiology. Alveolar macrophages and lung fibroblasts play key roles in maladaptive tissue remodelling; however, the cellular and molecular mechanisms underlying their coordinated fibrotic responses remain incompletely characterised. Methods: Following influenza A virus (IAV) infection, viral load, cytokine release and transcriptomic changes were analysed. To assess indirect effects on fibrosis, IMR-90 fibroblasts were treated with conditioned media from infected alveolar macrophage-like (AML) cells. Direct IAV infection of IMR-90 cells was also performed to evaluate changes in the Hippo signalling pathway and fibrotic marker expression using microarray and transcriptomic approaches. Results: For the first time, AML cells were successfully infected with IAV, validating this model for studying pathogen-driven exacerbation of fibrosis in ageing lungs. Transcriptomic and protein-level analyses revealed that IAV promotes fibrogenesis in fibroblasts through two distinct mechanisms: 1) indirectly, Conclusions: These findings provide novel mechanistic insights into macrophage-fibroblast crosstalk in the context of viral infection and fibrosis. They suggest that dysregulation of these interactions contributes to the susceptibility of the ageing lung to fibrotic remodelling following respiratory viral infections and may inform future therapeutic interventions targeting Hippo pathway signalling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.